OncoHost Launches NSCLC Cancer Test in the United States
Original source here.
Israel-based OncoHost recently announced the official launch of its PROphet non-small cell lung cancer (NSCLC) test in the United States.
PROphet guides first-line treatment decisions for advanced unresectable NSCLC patients. It gives clinicians actionable clinical insights into optimal first-line therapeutic choices and a better understanding of their patients’ personalized cancer dynamics. In one pretreatment blood test, PROphet scans approximately 7,000 proteins in patients’ plasma and delivers a report that predicts their clinical benefit from anti-programmed death 1/anti-programmed death ligand 1 (anti-PD-1/PD-L1) immunotherapy-based treatment plans.
The PROphet algorithm is trained on OncoHost’s large-scale clinical trial, which has more than 1,500 patients from 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field. The NSCLC test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans, the company noted.
OncoHost officials said that although driver mutation detection is an essential factor in determining effective treatment, approximately 85% of all patients diagnosed with NSCLC do not have any detectable driver mutations. In these cases, the test, when combined with PD-L1 results, helps predict the best treatment plan for each individual patient.
The officials added that the PROphet report will offer personalized insights on the predicted clinical benefit of immunotherapy.